The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
TCL
Vol.
31
No.
28
July 15, 2005
- NIH review finds 44 scientists violated ethics rules on industry consulting, House committee chairman says.
- NIH reauthorization to be topic of July 19 hearing.
- Advisors seek support for NCI’s “special authorities” granted in 1971.
- Also in this 8-page issue: Senate Labor-HHS finds an extra $1 billion for NIH; Appropriations Committee reports bill to Senate.
- Advisors say NCI needs to reach out to other fields.
- Brain tumor foundations form collaboration.
TCL
Vol.
31
No.
30
July 29, 2005
- More money would speed progress, NCI says, but backs off previous commitment to meet 2015 goal by 2010.
- In Senate testimony, NCI director uses survival rate as measure of progress for goal to “eliminate suffering and death due to cancer.”
- Also in this 8-page issue: Use cancer mortality, not 5-year survival, to track progress against cancer, researchers say.
- Obituary: Sir Richard Doll, 92, epidemiologist who linked smoking to lung cancer.
CCL
Vol.
28
No.
7
July 29, 2005
- Children, Parents Differ In Decisionmaking On Cancer Treatment, Survivor Study Finds
- Majority Of U.S. Cancer Patients Receive High-Quality Care, ASCO Study Finds
- Velcade Improves Survival In Relapsed Multiple Myeloma
- Tobacco Linked To 63 Percent Of Cancer Deaths In Black Men
- Black Women More Likely To Delay Diagnosis, Treatment
- Study Finds Trial Results Reliable At Three Years
- Taxotere Added To Regimen Improves Survival, Study Finds
- NCI-Approved Clinical Trials
TCL
Vol.
31
No.
31
August 05, 2005
- An “insurgency” targets randomized trials, demands access to investigational drugs.
- In this 16-page issue: The Wall Street Journal editorial page leads campaign against efficacy standard.
- Critics of FDA misunderstand Bayesian analysis, statisticians say.
- Abigail Alliance says statisticians usurped control of oncology. Milken’s optimism fuels the movement.
- Gottlieb questions ODAC’s independence.
CCL
Vol.
28
No.
8
August 26, 2005
- Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds
- NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer
- Two-Point Rise In PSA Signals High-Risk Prostate Cancer
- High Cervical Cancer Rates Indicate Access Problems
- Lifestyle Changes Common After Cancer Diagnosis
- Proton Beam Radiation Helps Cancer Patients Retain Vision
- Cooperative Group Trials Approved By NCI Are Listed
TCL
Vol.
31
No.
32
September 09, 2005
- House committee asks GAO to investigate Klausner-era NCI contract with Harvard University.
- Also in this 8-page issue: John Niederhuber joins NCI as special advisor, quits NCAB. Harold Freeman steps down as NCI disparities head.
- Final NIH ethics rules retain consulting ban, but limit divesture requirement to senior employees.
- Assembly of Scientists, started as a result of conflict of interest controversy, plans Sept. 14 meeting.
- Hurricane Katrina: Cancer groups, NCI offer help to displaced patients and caregivers.
TCL
Vol.
31
No.
33
September 16, 2005
- Richard Klausner resigned from the Gates Foundation, saying move was unrelated to Congressional investigation of NCI contract to Harvard University during Klausner’s tenure as NCI director.
- FDA’s Oncologic Drugs Advisory Committee recommended approval of three drugs for cancer, voted down one.
- Three cancer centers joined the Multiple Myeloma Research Consortium.